Whole blood propionylcarnitine in newborns with orofacial cleft

Kamil K Hozyasz1, Mariusz Oltarzewski, Iwona Lugowska

  • 1Departments of Pediatrics, Pediatric Surgical Oncology and Pediatric Surgery and Neonatal Screening Laboratory, Institute of Mother and Child, Warsaw, Poland. khozyasz@verco.com.pl

Insights

This study found no significant difference in propionylcarnitine levels between newborns with orofacial clefts and controls. Maternal vitamin B12 deficiency, indicated by elevated propionylcarnitine, does not appear to be a risk factor for cleft lip and palate.

Area of Science:

  • Biochemistry
  • Genetics
  • Developmental Biology

Background:

  • Orofacial clefts result from complex genetic and environmental interactions.
  • Vitamin B12 plays a role in preventing certain birth defects, as shown in animal studies.
  • Elevated propionylcarnitine in newborns suggests maternal vitamin B12 deficiency.

Purpose of the Study:

  • To investigate the association between increased propionylcarnitine levels in newborns and orofacial clefts.
  • To determine if maternal vitamin B12 deficiency is a risk factor for cleft lip with or without cleft palate (CLP).

Main Methods:

  • A retrospective study comparing 52 newborns with isolated CLP to 107 unaffected control newborns.
  • Whole blood propionylcarnitine concentrations were quantified using tandem mass spectrometry.
  • Statistical analysis using a T-test for equality of means was performed.

Main Results:

  • The mean propionylcarnitine concentration in newborns with clefts was 2.82±1.06µmolL⁻¹.
  • The mean propionylcarnitine concentration in control newborns was 2.68±0.94µmolL⁻¹.
  • No statistically significant difference was found between the two groups (P=0.381).

Conclusions:

  • Maternal vitamin B12 deficiency, indicated by elevated propionylcarnitine, does not appear to be a significant risk factor for CLP in this study population.
  • Further research may be needed to fully elucidate the role of vitamin B12 in orofacial cleft development.